Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Reiterated by Wedbush

Wedbush reiterated their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report issued on Tuesday morning, RTT News reports. The brokerage currently has a $33.00 target price on the stock.

DAWN has been the subject of several other reports. HC Wainwright reduced their price target on Day One Biopharmaceuticals from $50.00 to $40.00 and set a buy rating for the company in a research report on Tuesday. Piper Sandler reaffirmed an overweight rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Needham & Company LLC reaffirmed a buy rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research report on Monday, April 22nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $37.67.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $17.08 on Tuesday. The stock has a 50 day moving average price of $15.47 and a 200 day moving average price of $14.12. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The stock has a market capitalization of $1.49 billion, a PE ratio of -7.18 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, research analysts forecast that Day One Biopharmaceuticals will post -2.67 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the transaction, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The disclosure for this sale can be found here. Insiders sold 195,247 shares of company stock worth $3,376,817 in the last ninety days. 8.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. First Turn Management LLC acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at $24,834,000. TimesSquare Capital Management LLC raised its holdings in Day One Biopharmaceuticals by 45.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock valued at $24,325,000 after acquiring an additional 523,455 shares in the last quarter. Braidwell LP raised its holdings in Day One Biopharmaceuticals by 13.5% in the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares in the last quarter. Finally, Superstring Capital Management LP acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at $5,543,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.